Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma
- 1 February 2014
- journal article
- Published by Elsevier in Human Pathology
- Vol. 45 (2) , 259-267
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosisLaboratory Investigation, 2012
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Heteroclitic serological response in esophageal and prostate cancer patients after NY‐ESO‐1 protein vaccinationInternational Journal of Cancer, 2011
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1Journal of Clinical Oncology, 2011
- When MAGE meets RING: insights into biological functions of MAGE proteinsProtein & Cell, 2011
- Use of Immunohistochemistry in the Diagnosis of Melanocytic Lesions: Applications and PitfallsFuture Oncology, 2010
- NY‐CO‐58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancerInternational Journal of Cancer, 2009
- Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanomaNature Clinical Practice Oncology, 2008
- Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors.2007
- Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancerJournal of Clinical Pathology, 2001